This publication presents the data and findings of the risk assessment on methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA), carried out by the extended Scientific Committee of the EMCDDA on 22 July 2016. MDMB-CHMICA is the first synthetic cannabinoid receptor agonist to be risk-assessed by the EMCDDA. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 27 February 2017, the Council decided that MDMB-CHMICA should be subject to control measures across the Member States.

Table of contents:
• Foreword
• EMCDDA actions on monitoring and responding to new drugs
• EMCDDA–Europol Joint Report on MDMB-CHMICA — a summary
• Risk Assessment Report on a new psychoactive substance: MDMB-CHMICA
• Annex 1: Technical report on MDMB-CHMICA
• Council Decision on subjecting MDMB-CHMICA to control measures
• Participants of the risk assessment meeting